Carsten Utoft Niemann

Research interests

Publications

• ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia

  Annals of Oncology · 2024 · https://doi.org/10.1016/j.annonc.2024.06.016

• Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

  Blood · 2024 · https://doi.org/10.1182/blood.2024024631

• Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

  The Lancet Oncology · 2023 · https://doi.org/10.1016/s1470-2045(23)00452-7

• First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2213093

• Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2200006

• COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

  Leukemia · 2021 · https://doi.org/10.1038/s41375-021-01450-8

• Machine learning can identify newly diagnosed patients with CLL at high risk of infection

  Nature Communications · 2020 · https://doi.org/10.1038/s41467-019-14225-8

• Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30443-5

• COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

  Leukemia · 2020 · https://doi.org/10.1038/s41375-020-0959-x

• Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.09.019

• Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

  Blood · 2020 · https://doi.org/10.1182/blood.2020007039

• Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

  The Journal of Infectious Diseases · 2020 · https://doi.org/10.1093/infdis/jiaa446

• Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1815281

• Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment

  Blood Advances · 2019 · https://doi.org/10.1182/bloodadvances.2019000360

• Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

  The Lancet Haematology · 2018 · https://doi.org/10.1016/s2352-3026(18)30018-8

• Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

  Blood · 2018 · https://doi.org/10.1182/blood-2017-12-820910

• ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation

  Leukemia · 2018 · https://doi.org/10.1038/s41375-017-0007-7

• TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

  Blood · 2017 · https://doi.org/10.1182/blood-2017-04-779736

• Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project

  Cytometry Part B Clinical Cytometry · 2017 · https://doi.org/10.1002/cyto.b.21595

• Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.11

• The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

  Clinical Cancer Research · 2016 · https://doi.org/10.1158/1078-0432.ccr-16-0463

• Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

  Haematologica · 2015 · https://doi.org/10.3324/haematol.2015.126672

• Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study

  Clinical Cancer Research · 2015 · https://doi.org/10.1158/1078-0432.ccr-15-1965

• Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

  Leukemia · 2014 · https://doi.org/10.1038/leu.2014.122

• Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)71182-9

• B-cell receptor signaling as a driver of lymphoma development and evolution

  Seminars in Cancer Biology · 2013 · https://doi.org/10.1016/j.semcancer.2013.09.001

Current projects

No projects listed.